Peter Flachenecker

Fatigue in multiple sclerosis: a comparison of different rating scales and correlation to clinical parameters

Peter Flachenecker, Tania Kümpfel, Boris Kallmann et al. · Multiple Sclerosis Journal · 2002 · 635 citations

Medicine, Neurology, Neuroimmunology +14

PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS

G. Francis, Richard AC Hughes, John King et al. · DIAL (Catholic University of Leuven) · 2001 · 472 citations

Pharmacy, Internal Medicine, Pharmacotherapy +8

Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension

Raju Kapoor, Pei‐Ran Ho, Nolan Campbell et al. · The Lancet Neurology · 2018 · 337 citations · Full text

Life Sciences, Neurology, Pharmacotherapy +14

Validation of the Multiple Sclerosis International Quality of Life questionnaire

M.C. Simeoni, Pascal Auquier, Óscar Fernández et al. · Multiple Sclerosis Journal · 2007 · 197 citations

Pharmacy, Neurology, Health Assessment +16

Cytokine mRNA expression in patients with multiple sclerosis and fatigue

Peter Flachenecker, Irene Bihler, Frank Weber et al. · Multiple Sclerosis Journal · 2004 · 168 citations

Life Sciences, Immunology, Immunopathology +16